OncoMatch/Clinical Trials/NCT06663319
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Is NCT06663319 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including JNJ-89402638 and Bevacizumab for colorectal neoplasms.
Treatment: JNJ-89402638 · Bevacizumab · FOLFOX · FOLFIRI — The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MLH1 wild-type
Required: MLH1 wild-type
Required: MSH2 wild-type
Required: MSH2 wild-type
Required: MSH6 wild-type
Required: MSH6 wild-type
Required: PMS2 wild-type
Required: PMS2 wild-type
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: fluoropyrimidine and irinotecan doublet (FOLFIRI) — metastatic/unresectable CRC
Participants must have previously received a fluoropyrimidine and irinotecan doublet (such as FOLFIRI)
Cannot have received: irinotecan for metastatic disease (irinotecan)
Must not have received irinotecan previously for metastatic disease
Lab requirements
Kidney function
gfr >= 30 ml/min based on mdrd 4-variable formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado Denver Anschultz Medical Campus · Aurora, Colorado
- Florida Cancer Specialists · Sarasota, Florida
- Community Health Network · Indianapolis, Indiana
- Start Midwest · Grand Rapids, Michigan
- Swedish Cancer Institute · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06663319 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior irinotecan for metastatic disease disqualifies patients from enrollment.
Does this trial require MLH1?
Yes, MLH1 wild-type is a required biomarker for enrollment.
Does this trial require MLH1?
Yes, MLH1 wild-type is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages